Publications
- Sun Hao, Emily Berg and Zhengyuan Zhu. (2021) “Bivariate small‐area estimation for binary and gaussian variables based on a conditionally specified model”. Biometrics. doi
- Sun, Hao (2023) “Small area estimation and graphical model for complex surveys” Iowa State University link
- Sun, Hao, Emily Berg, and Zhengyuan Zhu (2023). “Multivariate Small-area Estimation for Mixed-type Response Variables With Item Nonresponse.” Journal of Survey Statistics and Methodology. doi
- Fleming, S., Roboz, G.J., Fathi, A.T., Zhang, T.Y., Wei, A., Carraway, H.E., Holes, L., Petrlik, E., Prebet, T., de Menezes, D.L., Bluemmert, I., Sun, H., and Ravandi, F. (2023) “Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia” Journal of Clinical Oncology doi
- Fleming, S., Roboz, G.J., Fathi, A.T., Zhang, T.Y., Wei, A., Carraway, H.E., Holes, L., Petrlik, E., Prebet, T., Lopes de Menezes D., Bluemmert, I., Sun, H., Ravandi, F. (2023) “P567: Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia” HemaSphere doi
- Fleming, S., Roboz, G.J., Fathi, A.T., Zhang, T.Y., Wei, A., Carraway, H.E., Holes, L., Petrlik, E., Prebet, T., Lopes de Menezes D., Bluemmert, I., Sun, H., Ravandi, F. (2023) “AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)” Clinical Lymphoma, Myeloma and Leukemia doi